Dermatology Month in Review: June 2025

The HCPLive team publishes a new edition of our Month in Review series every month, providing a summary highlighting the most significant news coverage from the month in each of our medical subfields. In this iteration, HCPLive highlights some of the most notable stories in the field of dermatology.

The dermatology field in June had a variety of news stories break on an array of dermatologic conditions. New research, US Food and Drug Administration (FDA) news, and interviews with leaders in the field of dermatology were all highlighted in June. A feature interview covering the interaction between the gut microbiome and skin health was released this month as well, along with 2 new episodes of the Skin of Color Savvy podcast and 1 of the Medical Sisterhood podcast. The following summarizes some of the most notable dermatology news coverage featured in June:

FDA Approves Dupilumab (Dupixent) for Bullous Pemphigoid in Adult Patients

In 1 notable FDA-related development in June, dupilumab (Dupixent) was approved for the treatment of adults living with bullous pemphigoid. The June 20, 2025, decision by the FDA announced by Sanofi and Regeneron was based upon positive clinical trial data drawn from the ADEPT program. The approval makes dupilumab the first targeted therapy from the FDA as well as the 8th indication for dupilumab in a disease with underlying type 2 inflammation.

FDA Extends Review Period of Ruxolitinib Cream for Children with Atopic Dermatitis

Another notable piece of FDA news in June was the organization's extention of its period of review for ruxolitinib cream (OPZELURA) for children ages 2 - 11 years with mild-to-moderate atopic dermatitis. This extension was announced despite the previous target action date having been set for June 2025. According to Incyte, the new Prescription Drug User Fee Act (PDUFA) target action date is now pushed to September 19, 2025. Ruxolitinib cream’s supplemental New Drug Application (sNDA) was previously accepted for review following positive data drawn from the phase 3 TRuE-AD3 trial. These data had pointed to the drug’s efficacy in pediatric patients with atopic dermatitis.

The Medical Sisterhood—The Global Sisterhood: When She Speaks the World Listens

In 1 of June's most notable podcast episodes, The Medical Sisterhood featured host Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale University School of Medicine and the associate director of clinical trials at Central Connecticut Dermatology Research, alongside Canadian dermatologist and thought leader Melinda Gooderham, MD, MSc, the Medical Director of the SKiN Centre for Dermatology. The 2 held a candid and in depth conversation on the building of a high-impact career in dermatology while navigating the complexities of motherhood, self-doubt, and leadership.

Skin of Color Savvy: Live at RAD 2025 with Tiffany Mayo, MD, and Raj Chovatiya, MD, PhD

A special on-site episode of Skin of Color Savvy: The Art and Science of Treating Patients of Color was also released in June during the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville. The show, produced by the Skin of Color Society (SOCS) and HCPLive, included dermatologists Raj Chovatiya, MD, PhD, and Tiffany Mayo, MD, who delved into a wide-ranging discussion highlighting atopic dermatitis in skin of color. These 2 leaders in dermatology recorded the podcast on-site at RAD, discussing diagnostic challenges, patient communication, and the future of topical therapy, noting clinical insights and actionable strategies for improving care across the range of diverse skin types.

Skin of Color Savvy: News Update—The Power of Mentorship & Collaboration in Medicine

In June's News Update episode of Skin of Color Savvy, board-certified dermatologist, 'The Gorgeous Plate' podcast host Aleta Simmons, MD, provided an in-depth discussion to the SOCS podcast. Simmons is also known for her work as the founder of Simmons Skin Center in Nashville, Tennessee, and as thecreator of the educational platform Get the Skin-E. She spoke with the HCPLive team about the power of mentorship, the value of interdisciplinary collaboration, and her mission to bring a holistic, human-centered approach to dermatologic care.

Breaking Down Silos: Integrating GI and Dermatology for Inflammatory Disease Care

Given that the intersection between dermatology and gastroenterology has emerged as a topic of note in the field of dermatology, and given the growing recognition of shared pathophysiology between chronic skin and gut disorders, a new video feature was released by HCPLive that highlighted this topic and the need for interdisciplinary collaboration. This Special Report episode featured Raj Chovatiya, MD, PhD, a clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and as founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and Adelina Hung, MD, a clinical assistant professor at Rosalind Franklin University Chicago Medical School and director of the IBD program at Sinai Health System Chicago. The 2 leaders in their respective fields explored the growing clinical and research intersections between dermatology and gastroenterology.